AstraZeneca's woes continue
AstraZeneca has admitted it faces another difficult year of falling sales in 2013 after patent expiries last year meant revenues slumped 17 per cent to £27.9bn.
Pascal Soriot, the new chief executive of Britain's second-biggest drug maker, was parachuted in from rival Roche last year after David Brennan quit under pressure from disappointed shareholders. Mr Soriot warned that revenues will face a "mid-to-high single-digit percentage decline" this year. That follows pre-tax profits for 2012 coming in 38 per cent lower than the previous year, at £7.7bn.
The news was even worse than City analysts had expected, and the shares fell 99.5p to 3,053p.
Astra's revenue stream is drying up as some of its key drugs are having to compete against cheaper generic rivals. The blockbusters Nexium and Crestor lose the crucial United States patent protection in 2014 and 2016.
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
Ball pool for adults opens in London
Amal Clooney gives excellent response to fashion question at European Court of Human Rights
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...
Competitive salary & benefits!: MBDA UK Ltd: MBDA UK LTD Indirect Procurement...